MIRA Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRA research report →
Companymirapharmaceuticals.com
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.
- CEO
- Erez Aminov
- IPO
- 2023
- Employees
- 2
- HQ
- Baltimore, MD, US
Price Chart
Valuation
- Market Cap
- $40.66M
- P/E
- -4.14
- P/S
- 0.00
- P/B
- 4.34
- EV/EBITDA
- -3.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -140.83%
- ROIC
- -104.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,442,485 · -32.98%
- EPS
- $-1.35 · -164.71%
- Op Income
- $-10,493,112
- FCF YoY
- 16.17%
Performance & Tape
- 52W High
- $2.45
- 52W Low
- $0.90
- 50D MA
- $1.05
- 200D MA
- $1.32
- Beta
- 1.50
- Avg Volume
- 153.13K
Get TickerSpark's AI analysis on MIRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | Aminov Erez | other | 83,500 |
| Dec 17, 25 | Aminov Erez | other | 3,155,170 |
| Oct 16, 25 | Aminov Erez | other | 379,000 |
| Oct 16, 25 | Aminov Erez | other | 234,595 |
| Oct 1, 25 | Shekhat Denil Nanji | other | 22,378 |
| Oct 1, 25 | Aminov Erez | other | 2,685,456 |
| Sep 18, 25 | Aminov Erez | other | 150,000 |
| Aug 29, 25 | Aminov Erez | other | 62,500 |
| May 15, 25 | Weichselbaum Alan | other | 75,000 |
| Dec 9, 24 | Whalen Matthew Pratt | other | 25,000 |
Our MIRA Coverage
We haven't published any research on MIRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MIRA Report →